ERBB2 and breast cancer: According to the International Breast Cancer Study Group trials, in early-stage HER2-positive breast cancer, the 10-year cumulative incidence rate of central nervous system metastasis was approximately 7 % for HER2-positive tumors, compared to a rate of 3.5 % for HER2-negative tumors [6].